Gevorg Tamamyan: If You are Visible on OncoDaily, You are Visible in Oncology
PSMAddition: [177Lu]Lu-PSMA-617 Improves Radiographic PFS in PSMA-Positive mAPMN/S Prostate Cancer
Ada Waks: Therapeutic Strategy for CDK4/6i-Resistant HR+ Metastatic Breast Cancer
Two Worlds, One Mission How a Canada–Nepal Partnership Is Transforming Global Oncology Education
VIRO 2026 Brings Global Voices Together in Renal Oncology
The Main Types of Chemotherapy Drugs and How They Work
Beyond the Placental Barrier: Chemotherapy During Pregnancy
Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives.
The ABC Global Alliance, established in 2016 as an initiative of the European School of Oncology and now registered as a non-profit association in Portugal, is a multi-stakeholder platform for all those interested in collaborating on common projects related to advanced breast cancer (ABC) around the world. We are made up of people and organisations who are committed to develop, promote and support tangible improvements that will ultimately create awareness and actions that will improve and extend the lives of patients living with ABC worldwide. The ABC Global Alliance was launched during the World Cancer Congress in Paris on 3 November 2016. It is a continuation of the work developed through the ABC International Consensus Conference created in 2011, responsible for the ESO-ESMO international consensus guidelines for the management of advanced breast cancer and its advocacy efforts.
Access Cancer Treatment (ACT) for Children is a multi-stakeholder initiative uniting industry, the medical community, and patient advocates to safely introduce innovative child cancer therapies in LMICs. ACT for Children uses a hospital-centered, local support model with three pillars: access to quality-assured innovative medicines expert medical management patient-centered supportive care ACT for Children generates data to inform policy and investment, establishes clinical guidance for the use of innovative medicines in LMIC settings, and builds toward sustainable access.
The AIM-HI Accelerator Fund (AIM-HI) is a 501(C)(3) non-profit organization created in 2019 by the National Foundation for Cancer Research to provide oncology startups with the resources they need to drive innovative discoveries forward, out of the lab, to the clinics, and eventually to the people battling cancer. Our mission is to bridge the gap between research breakthroughs and clinical trials, aiming to develop innovative cancer therapies and technologies that can save patients’ lives.
Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to help people with cancer live longer. Located in the San Francisco bay area, Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus has an ambitious undertaking and expects to become a force in the discovery, development and commercialization of novel combination therapies to treat cancer in areas of high unmet need. Our employees enjoy operating in an exceptionally dynamic and team-driven environment in which the “rule book” has not yet been written.
The Asian Fund for Cancer Research Limited (AFCR) is committed to funding cancer research, especially those cancers prevalent in Asian populations, and promoting global collaborations for high impact to save the lives of cancer patients. AFCR focuses on funding “high-risk, high-impact” cancer research areas with the greatest potential to benefit Asian cancer patients. AFCR provides critically needed research support and networks to cancer researchers and clinicians. AFCR promotes cancer awareness and prevention education to the Asian public.
AVEO, in partnership with LG Chem, is on a mission to help those with cancer move forward with treatment that is effective and allows them to carry on with their daily lives. Together, AVEO and LG Chem Life Sciences will: Extend the commercial footprint of LG Chem into the US Diversify and expand the combined pipeline for both companies Accelerate continued growth through the development and commercialization of innovative cancer therapies
Big Whig Media is a full-service media production facility and agency located in the heart of Washington, D.C. Our video production and broadcast facility offers Satellite Media Tours (SMTs), Media Training, flash cams for breaking news, full post-production editing, color grading services and broadcast studios, including our sky studio, complete with views of Pennsylvania Avenue, the U.S. Capitol, and the Washington Monument. To learn more about Big Whig Media, follow us on LinkedIn, and visit our website.
The Chinese Anti-Cancer Association (CACA), founded in 1984, has a mission to unite people involved in all branches of oncology and others with a similar interest in fighting cancer. CACA aims its utmost efforts at organizing scientific cooperation and conferences, promoting international non-governmental exchanges, conducting various training courses and seminars, fostering scientific, technological and medical personnel in the field of oncology, compiling and publishing academic periodicals, and mobilizing social forces to take part in popularization and dissemination of the knowledge of tumor prevention. Globally, the association is interested in organizing academic meetings with international colleagues in order to cultivate friendly ties with overseas oncology organizations and individuals. The Chinese Anti-Cancer Association has been a full UICC member since January 1997.
ECHoS is an European project, funded by Horizon Europe Programme, that aims to support the implementation of the Cancer Mission activities in all Member State and Associated Country (MS/AC) through the establishment and development of National Cancer Mission Hubs (NCMHs) operating at national, regional, and local levels. By establishing NCMHs in each MS/AC, European citizens and organisations in health, research, and beyond, will be voiced and their voices will echo together.
The Egyptian Cancer society (ECS) was founded in 1991 as a branch of Egyptian medical association, it is an independent non-profit association and dose not issue licenses.
We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.
The Emirates Oncology Society is dedicated to promoting and fostering the multidimensional care of cancer patients throughout the United Arab Emirates, by bringing together all of the practising cancer specialists across all disciplines. To help our cancer patients face one of the greatest challenges in their lives and be cured of their disease, their treating physicians, surgeons, radiation therapists, oncology nurses, social workers, pharmacists, cancer researchers and dietitians require easy access to the latest scientific knowledge and technology available. The EOS aims to provide its members with cutting-edge information to make this goal a measurable reality for all of patients.
The GI Cancers Alliance is the collective voice of the GI cancer community working alongside our members to raise awareness, provide education, and keep the patient voice central to advocacy.
The Hellenic Cancer Federation (ELLOK) is the voice of cancer patients in Greece, serving as a nationwide organization that unites and represents associations and organizations working in the field of cancer prevention and treatment. With a vision to fully support patients and their families, as well as to ensure access to quality healthcare services for all, ELLOK strives to raise awareness in society, promote research and advocate for access to innovative therapies. Through collaboration with government bodies, healthcare professionals, and scientific organizations, ELLOK works towards the development of health policies that place the patient at the center and promote equality in healthcare.
Hope For Stomach Cancer is a 501(c)(3) non-profit organization that provides resources to patients, caregivers and loved ones while promoting early detection and prevention to the general and medical communities. Hope creates and facilitates programs that enable those affected by stomach cancer to take actionable steps to live the best possible life through each phase of the disease. Hope For Stomach Cancer is the dba name for the Stomach Cancer Awareness Network.
The International Cardio-Oncology Society is committed to raising awareness about cardiovascular disease that commonly occurs in patients undergoing treatment for cancer. The ongoing success and complexity of current life-saving therapies has led to the recognition by healthcare providers, patients, and caregivers that cardiac health is vitally important in order to obtain the best patient outcomes. We aim to enhance recognition among providers that prevention and early detection of cardiovascular disease is essential to providing optimal protection for our patients.
Every year, hundreds of oncologists and specialists from across the region arrive with a shared conviction: that better knowledge leads to better outcomes for patients. That conviction is what built the International School of Clinical Oncology, and what has driven it forward, year after year, into one of the region’s most respected platforms for oncology education and collaboration. ISCO is a school in the fullest sense of the word. Through regular educational meetings, structured clinical programs, cross-border knowledge exchange, and a faculty drawn from leading centers across Europe: the United Kingdom, Italy, Spain, and beyond to deliver world-class education that meets oncologists where they are and elevates where they can go. Each annual congress is accredited by ASCO and ACCME, and proudly endorsed by Institut Gustave Roussy (IGR), Paris, one of the world’s foremost cancer centers, a partnership that reflects the standard of excellence ISCO holds itself to. But ISCO’s impact extends well beyond the congress hall. Through regular educational meetings, continuous medical education, and the exchange of clinical programs across borders, ISCO sustains a living, breathing community of practice, the one where knowledge moves freely and innovation is a shared pursuit. Central to that mission is the ISCOlarship (the annual scholarship at IGR) : ISCO’s commitment to the next generation of oncologists. Awarded annually since 2022, the ISCOlarship recognizes emerging talent and invests directly in the future of the field, because advancing oncology means advancing the people who practice it. ISCO is not just a school. It is a movement built on the belief that every oncologist, regardless of geography, deserves access to the same knowledge, the same conversations, and the same opportunity to grow.
The King Hussein Cancer Foundation (KHCF) is an independent, non-governmental, non-profit, national foundation founded in 2001 by Royal Decree and headed by HRH Princess Ghida Talal. HRH Princess Ghida presides over all management functions and operations of the King Hussein Cancer Foundation (KHCF) and Center (KHCC) along with a board of trustees comprised of a dedicated group of prominent volunteers who are experts in the fields of health, economy and finance. The Board of Trustees oversees the work of: The King Hussein Cancer Foundation (KHCF) - Fundraising, Advocacy and Development The King Hussein Cancer Center (KHCC) - Comprehensive Cancer Care and Research
The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization co-founded in 1973 by Nobel Laureate Dr. Albert Szent-Györgyi and Attorney/Business Entrepreneur Franklin Salisbury, Sr. NFCR provides scientists in the lab the critical seed funding they need to make game-changing discoveries in cancer detection, treatments, and prevention and ultimately, a cure for all cancers. NFCR has distinguished itself in the cancer research sector by emphasizing “high-risk, high-impact” long-term and transformative pioneering research fields, often overlooked by other major funding sources. With the support of more than 5.7 million individual donors over the last 53 years, NFCR has provided $420 million in funding to cancer research, prevention, and public education. NFCR-supported research has led to some of the most significant life-saving discoveries that benefit patients today.
Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D.
The mission of the Society for Integrative Oncology is to advance evidence-based, comprehensive integrative healthcare to improve the lives of people affected by cancer. SIO has consistently encouraged rigorous scientific evaluation of both pre-clinical and clinical science, while advocating for the transformation of oncology care to integrate evidence-based complementary approaches. The vision of SIO is to have research inform the true integration of complementary modalities into oncology care, so that evidence-based complementary care is accessible and part of standard cancer care for all patients across the cancer continuum. As an interdisciplinary and interprofessional society, SIO is uniquely poised to lead the “bench to bedside” efforts in integrative cancer care.
Sharing Progress in Cancer Care (SPCC), an independent non-profit organisation registered in Switzerland, was founded in 2019 as a spin-off of the European School of Oncology. SPCC is committed to driving progress in cancer care by fostering and sharing innovation, new knowledge, and best practices through its global educational activities. SPCC delivers impactful evidencebased programmes in cancer care, accessible both on-line and in person. It also provides a wealth of resources through its digital channels, including its dedicated platform, OncoCorner. SPCC aims to increase access to best education bringing the cancer community players together in a sharing and learning dialogue worldwide, from academic and clinical research institutions, oncologists, hematologists, general practitioners, medical students and their associations to pharmaceutical, biotech and medtech companies, government departments, policymakers, regulatory bodies, and patient advocacy and support associations. In addition, SPCC develops and promotes Request for Proposal (RFP) projects and custom-designed instructional and training programmes for European-funded projects and for private sector partners. SPCC is actively engaged in a wide range of progressive, innovative topics, including: • Precision medicine and genomics-based therapies • Artificial intelligence and data-driven decision-making tools • Innovative care delivery models, such as integrated oncology and multidisciplinary teams • Digital health solutions, including telemedicine and remote monitoring • Patient-centered approaches that enhance quality of life, engagement, and shared decision-making • Equity-driven innovations that address disparities in access to treatment and outcomes The goal of SPCC is to ensure that care becomes more personalised, efficient, equable, and sustainable, ultimately improving survival rates and the overall experience of patients and their families.
Recognized as one of the top 20 research universities worldwide, our culture of collaboration sparks discoveries that advance society and drive economic impact. Everything we do is dedicated to ensuring our students have the opportunity to become changemakers, equipped with the multidisciplinary tools needed to accelerate answers to our world’s most pressing issues.
US WorldMeds is a specialty pharmaceutical company that develops, licenses, and brings to market unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs.
ZS is a management consulting and technology firm that partners with companies to improve life and how we live it. We transform ideas into impact by bringing together data, science, technology and human ingenuity to deliver better outcomes for all. Founded in 1983, ZS has more than 15,000 employees in 40-plus offices worldwide. Everything we do is designed to strengthen your business strategy and product portfolio, turning insight into action and unlocking new opportunities for growth.
